212 related articles for article (PubMed ID: 32055299)
1. Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Wang XX; Sun SY; Dong QQ; Wu XX; Tang W; Xing YQ
Medchemcomm; 2019 Oct; 10(10):1740-1754. PubMed ID: 32055299
[TBL] [Abstract][Full Text] [Related]
2. Nitrobenzofurazan derivatives of N'-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1.
Paul S; Roy A; Deka SJ; Panda S; Trivedi V; Manna D
Eur J Med Chem; 2016 Oct; 121():364-375. PubMed ID: 27267006
[TBL] [Abstract][Full Text] [Related]
3. Role of indoleamine 2,3-dioxygenase in health and disease.
Yeung AW; Terentis AC; King NJ; Thomas SR
Clin Sci (Lond); 2015 Oct; 129(7):601-72. PubMed ID: 26186743
[TBL] [Abstract][Full Text] [Related]
4. Fused Heterocyclic Compounds as Potent Indoleamine-2,3-dioxygenase 1 Inhibitors.
Panda S; Roy A; Deka SJ; Trivedi V; Manna D
ACS Med Chem Lett; 2016 Dec; 7(12):1167-1172. PubMed ID: 27994758
[TBL] [Abstract][Full Text] [Related]
5. Discovery and preliminary structure-activity relationship of 1H-indazoles with promising indoleamine-2,3-dioxygenase 1 (IDO1) inhibition properties.
Qian S; He T; Wang W; He Y; Zhang M; Yang L; Li G; Wang Z
Bioorg Med Chem; 2016 Dec; 24(23):6194-6205. PubMed ID: 27769672
[TBL] [Abstract][Full Text] [Related]
6. Heme-containing enzymes and inhibitors for tryptophan metabolism.
Yan D; Lin YW; Tan X
Metallomics; 2017 Sep; 9(9):1230-1240. PubMed ID: 28650043
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a Novel Scaffold as an Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Based on the Pyrrolopiperazinone Alkaloid, Longamide B.
Shiokawa Z; Kashiwabara E; Yoshidome D; Fukase K; Inuki S; Fujimoto Y
ChemMedChem; 2016 Dec; 11(24):2682-2689. PubMed ID: 27863031
[TBL] [Abstract][Full Text] [Related]
8. Identification and preliminary structure-activity relationships of 1-Indanone derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors.
Gao D; Li Y
Bioorg Med Chem; 2017 Jul; 25(14):3780-3791. PubMed ID: 28526475
[TBL] [Abstract][Full Text] [Related]
9.
Yang D; Zhang S; Fang X; Guo L; Hu N; Guo Z; Li X; Yang S; He JC; Kuang C; Yang Q
J Med Chem; 2019 Oct; 62(20):9161-9174. PubMed ID: 31580660
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Novel Inhibitors of Indoleamine 2,3-Dioxygenase 1 Through Structure-Based Virtual Screening.
Zhang G; Xing J; Wang Y; Wang L; Ye Y; Lu D; Zhao J; Luo X; Zheng M; Yan S
Front Pharmacol; 2018; 9():277. PubMed ID: 29651242
[TBL] [Abstract][Full Text] [Related]
11. Indoleamine 2, 3-dioxygenase 1 inhibitory compounds from natural sources.
Tan Y; Liu M; Li M; Chen Y; Ren M
Front Pharmacol; 2022; 13():1046818. PubMed ID: 36408235
[No Abstract] [Full Text] [Related]
12. Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2.
Tijono SM; Palmer BD; Tomek P; Flanagan JU; Henare K; Gamage S; Braun L; Ching LM
Pharmaceuticals (Basel); 2022 Aug; 15(9):. PubMed ID: 36145311
[TBL] [Abstract][Full Text] [Related]
13. The expanding roles of 1-methyl-tryptophan (1-MT): in addition to inhibiting kynurenine production, 1-MT activates the synthesis of melatonin in skin cells.
Moreno AC; Clara RO; Coimbra JB; Júlio AR; Albuquerque RC; Oliveira EM; Maria-Engler SS; Campa A
FEBS J; 2013 Oct; 280(19):4782-92. PubMed ID: 23879623
[TBL] [Abstract][Full Text] [Related]
14. Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Röhrig UF; Majjigapu SR; Vogel P; Zoete V; Michielin O
J Med Chem; 2015 Dec; 58(24):9421-37. PubMed ID: 25970480
[TBL] [Abstract][Full Text] [Related]
15. The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
Gostner JM; Becker K; Überall F; Fuchs D
Expert Opin Ther Targets; 2015 May; 19(5):605-15. PubMed ID: 25684107
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Molecular Modeling Studies of N'-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Lee DH; Lee JY; Jeong J; Kim M; Lee KW; Jang E; Ahn S; Lee CH; Hwang JY
Molecules; 2017 Nov; 22(11):. PubMed ID: 29120388
[TBL] [Abstract][Full Text] [Related]
17. Preparation and evaluation of L- and D-5-[
Tang T; Gill HS; Ogasawara A; Tinianow JN; Vanderbilt AN; Williams SP; Hatzivassiliou G; White S; Sandoval W; DeMent K; Wong M; Marik J
Nucl Med Biol; 2017 Aug; 51():10-17. PubMed ID: 28511073
[TBL] [Abstract][Full Text] [Related]
18. Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening.
Sari S; Tomek P; Leung E; Reynisson J
Molecules; 2019 Nov; 24(23):. PubMed ID: 31795096
[TBL] [Abstract][Full Text] [Related]
19. Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington's disease.
Boros FA; Klivényi P; Toldi J; Vécsei L
Expert Opin Ther Targets; 2019 Jan; 23(1):39-51. PubMed ID: 30449219
[TBL] [Abstract][Full Text] [Related]
20. Indoleamine 2,3-dioxygenase 1 deficiency attenuates CCl4-induced fibrosis through Th17 cells down-regulation and tryptophan 2,3-dioxygenase compensation.
Zhong W; Gao L; Zhou Z; Lin H; Chen C; Huang P; Huang W; Zhou C; Huang S; Nie L; Liu Y; Chen Y; Zhou D; Lv Z
Oncotarget; 2017 Jun; 8(25):40486-40500. PubMed ID: 28465467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
